NV-101 (Nanovalent Pharmaceuticals)

N/A

Report date: 2025/10/28 15:11:33

Base Information

Drug NameNV-101 (Nanovalent Pharmaceuticals)
Drug Alias NameNV-101 (Nanovalent Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD99 antigen modulatorsTopoisomerase II inhibitors
TargetsCD99 antigenTopoisomerase II
Therapy Area/IndicationsSarcoma, Ewing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanovalent Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNanovalent Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSarcoma, Ewing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A